Penumbra, Inc. (PEN) is likely to grow in the coming quarters, backed by the strength exhibited in the Thrombectomy business. The company's robust portfolio expansion looks promising. However, the impact of forex woes is a headwind. Competitive disadvantages also add to the worry. In the past year, this Zacks Rank #3 (Hold) company has lost 16.2% against the industry's 17.8% growth and the S&P 500's 30.4% rise. The global healthcare provider company has a market capitalization of $8.67 billion. PEN beat on ...